PHARMACEUTICAL MARKET RESEARCH REPORTS

Industry Standard Research – ISR Reports – is a full-service pharmaceutical market research company operating exclusively in the life sciences industry and a sister company of BioProcess Online. Their syndicated and custom market research capabilities enable their customers to make smarter, more informed business decisions. You’ll find links to their pharmaceutical market syndicated research reports below.

ISR's market research reports are produced using direct feedback from decision-makers, which enables ISR to provide data on topics that, until now, were only attainable through custom research. With rigorous screening criteria and methodologies that include surveys, in-depth phone interviews, and focus groups, ISR gathers actionable information that is immediately applicable to their customers. Each report is available for to purchase online and you may also download free preview files. If you have any questions, please feel free to email info@ISRreports.com.

TRENDS AND MARKET OUTLOOKS

  • Bioprocessing Market Trends and Outsourcing Dynamics: 2020-2025 (3rd Edition)

    This market research report affords readers the opportunity to gain insight into the bioprocessing market and where it’s heading. This report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what our survey respondents predict the marketplace will look like in five years.

  • Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (4th Edition)

    This market research report goes into depth on the manufacturing aspect of biosimilars. Manufacturing these complex products in a cost efficient manner will be a critical component to successfully commercializing biosimilars and the anticipated boom.

  • Sterile Injectable Drug Product Manufacturing Market Outlook (3rd Ed.)
    Sterile Injectable Drug Product Manufacturing Market Outlook (3rd Ed.)

    This report explores which delivery formats drug innovators are using in their pipelines and portfolios, how likely innovators are to outsource manufacturing based on delivery device, and how these proportions will shift over the next five years.

  • Pharmaceutical Excipient Market Overview and Outlook
    Pharmaceutical Excipient Market Overview and Outlook

    This market research report offers readers the opportunity to gain insight into the biopharmaceutical excipient market and where it’s heading. Remaining aware of market dynamics and expected changes will enable readers to better make key decisions regarding excipient use and to help identify where competitive advantages may be gained.

  • Development vs Commercial Outsourced Manufacturing Practices: Biologics
    Development vs Commercial Outsourced Manufacturing Practices: Biologics

    This market research report explores how the decision-making process differs among drug innovators outsourcing development activities from those outsourcing commercial manufacturing when it comes to CMO/CDMO selection criteria, use patterns, preferences and perceived leadership.

  • Central Lab Benchmarking & Market Dynamics (2nd Ed.)
    Central Lab Benchmarking & Market Dynamics (2nd Ed.)

    This report will help both study sponsors and providers answer a number of questions relevant to selecting and evaluating central lab service providers. For the purpose of this report, “central lab” is defined as a vendor that supplies specimen collection kits, logistics services, safety alerts, and a wide variety of laboratory testing services as well as providing lab reports to investigators.

QUALITY BENCHMARKING AND SERVICE PROVIDER PERFORMANCE

  • Bioanalytical Labs Market Dynamics and Service Provider Performance
    Bioanalytical Labs Market Dynamics and Service Provider Performance

    Sponsors can use this report to evaluate their lab selection process. Bioanalytical labs can use it to learn how their company performs against competitors. Topics covered include lab selection and perceptions, lab performance, and lab service quality profiles.

  • Biologic Drug Product CDMO Benchmarking (5th Ed.)
    Biologic Drug Product CDMO Benchmarking (5th Ed.)

    This report provides pharmaceutical companies and contract manufacturers a comprehensive analysis of current outsourcing trends and practices, in addition to a quantitative analysis of CMO service quality.

DEPARTMENT MODELS AND STRUCTURES

  • The CMC Function: Best Practices and Optimization
    The CMC Function: Best Practices and Optimization

    ISR interviewed 15 CMC professionals at 14 Top 50 pharmaceutical and biotechnology companies, as well as one company outside the Top 50 to better understand the Chemistry Manufacturing and Controls function throughout the preclinical, clinical, and commercialization phases of the product development process.

ISR ARTICLES

  • Reactor Technology’s Influence On CDMO Selection

    In Q2, 2020, ISR asked 76 biopharma respondents that outsource commercialized products how much influence the contract manufacturer’s reactor technology has on their choice of CDMO. The data show that reactor technology factors into the decision for almost all outsourcers of commercial biologics (95%). Two-thirds of respondents said reactor technology has a moderate or a lot of influence over the decision.

  • Outsourcers Are Feeling Uneasy About Continuity of Supply

    ISR’s annual CDMO Benchmarking research asked if and how the COVID-19 pandemic has impacted outsourced manufacturing. Find out how complications have picked up from the first year, with more outsourcers relaying bigger obstacles when it comes to manufacturing, specifically with drug product.

  • Preference Among Users: New And Emerging Biopharma

    In Q3 2021, ISR asked new and emerging biopharma respondents (those with R&D <$500M) which CDMOs they are currently working with, and, if the choice were entirely up to them, which CDMO would they prefer to use for all biologic drug substance manufacturing. Catalent, Lonza, and Patheon lead the pack. 

  • Use Of Preferred Providers Among Large Molecule Outsourcers

    ISR surveyed outsourcers of biologic API and outsourcers of biologics drug products to ask whether their company uses a preferred providers list of contract manufacturers for outsourced manufacturing.

  • Have CDMO Selection Criteria Changed Over the Past Five Years?

    Industry Standard Research shares how CDMO selection criteria have changed over the past five years and links the attributes to Life Science Leader’s CDMO Leadership Awards categories. This information be used by biopharma companies to make more informed CMO selection decisions and by contract manufacturers to optimize operational and marketing strategies.

ABOUT ISR VIDEO